Eighty-seven (87) percent of Aetna Medicare Advantage members in 4-star plans or higher for 2024

Commitment to exceptional service for members across the nation drove a significant improvement in member experience ratings

Today, we’re excited to announce that 87 percent of Aetna Medicare Advantage (MA) members are in 2024 Medicare Advantage Prescription Drug (MAPD) plans that are rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). This represents a significant achievement, given the considerably more stringent CMS measurement criteria this year.

“We are committed to delivering outstanding experiences and driving improved health outcomes for our Medicare Advantage members.”

“We are committed to delivering outstanding experiences and driving improved health outcomes for our Medicare Advantage members,” said CVS Health President and CEO Karen S. Lynch. “Our strong 2024 Star Ratings for Aetna are a result of focused execution and seamless collaboration across our entire company. We remain unwavering in our efforts to drive continuous improvement to support our members now and well into the future.”